Home
Home

Bydureon

Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes

Once-Weekly Bydureon Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes
Yahoo/Business Wire

Bydureon Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes

Bydureon Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes
Yahoo/Business Wire

FDA nod fuels Bydureon vs. Victoza bout

FDA nod fuels Bydureon vs. Victoza bout
Fierce Pharma

Amylin Gets Its Yes; Now For The Hard Work

Amylin Gets Its Yes; Now For The Hard Work
Seeking Alpha

Amylin, Alkermes Long-Acting Diabetes Drug Wins FDA Approval on Third Try

Amylin, Alkermes Long-Acting Diabetes Drug Wins FDA Approval on Third Try
Bloomberg

The New Amylin - More Risk, More Potential

The New Amylin - More Risk, More Potential
Seeking Alpha

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com

Lilly, Amylin, Merck Diabetes Drug Risks Highlighted

Lilly, Amylin, Merck Diabetes Drug Risks Highlighted
Minyanville

Lilly/Amylin diabetes drug shows promise

Lilly/Amylin diabetes drug shows promise
Yahoo/InvestorsBusinessDaily

Bydureon FDA Action Date Set for January 28, 2012

Bydureon FDA Action Date Set for January 28, 2012
Pipeline Review